Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Renal Cell Carcinoma (RCC) Clinical Trials

6 recruiting trials for Renal Cell Carcinoma (RCC). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional...

Sponsor: GI Innovation, Inc.Enrolling: 35811 locations
RECRUITINGPhase 1NCT07419841

A Phase 1 Study of the Safety and Tolerability of CTX-10726

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2...

Sponsor: Compass TherapeuticsEnrolling: 702 locations
RECRUITINGNCT06916624

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET/CT in diagnosing primary, recurrent, and metastatic...

Sponsor: The Affiliated Hospital of Qingdao UniversityEnrolling: 401 location
RECRUITINGNCT07461090

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

To evaluate and compare clinical effectiveness (operative time, blood loss, hospital stay, complications and etc) and cost analysis' between laparoscopic nephrectomy and open...

Sponsor: Menoufia UniversityEnrolling: 601 location
RECRUITINGPhase 1NCT07369505

Sapu003 in Advanced mTOR-sensitive Solid Tumors

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced...

Sponsor: SAPU NANO (US) LLCEnrolling: 271 location
RECRUITINGPhase 1 / Phase 2NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic...

Sponsor: GI Innovation, Inc.Enrolling: 763 locations